StockNews.com initiated coverage on shares of MediciNova (NASDAQ:MNOV – Free Report) in a research report report published on Tuesday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.
MediciNova Stock Up 1.7 %
NASDAQ MNOV opened at $1.81 on Tuesday. MediciNova has a 52 week low of $1.12 and a 52 week high of $2.16. The firm has a 50 day moving average of $1.71 and a two-hundred day moving average of $1.49. The stock has a market capitalization of $88.77 million, a PE ratio of -10.65 and a beta of 0.75.
MediciNova (NASDAQ:MNOV – Get Free Report) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01. On average, equities research analysts expect that MediciNova will post -0.23 earnings per share for the current fiscal year.
MediciNova Company Profile
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Further Reading
- Five stocks we like better than MediciNova
- Conference Calls and Individual Investors
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Are Penny Stocks a Good Fit for Your Portfolio?
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Breakout Stocks: What They Are and How to Identify Them
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.